Trial Profile

A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evenamide (Primary)
Indications Schizophrenia
Focus Adverse reactions
Sponsors Newron Pharmaceuticals

Most Recent Events

05 Sep 2017 According to results presented at the 30th ECNP Congress, a protocol was amended in terms of ramdomisation from 3:1 to 1:1.
25 Mar 2017 Results presented at the 16th International Congress on Schizophrenia Research 2017, according to a Newron Pharmaceuticals media release.
25 Mar 2017 Results published in a Newron Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com